Last reviewed · How we verify

M923 — Competitive Intelligence Brief

M923 (M923) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (glycoengineered). Area: Immunology.

phase 3 Monoclonal antibody (glycoengineered) IgG Fc glycosylation / Fc receptors Immunology Biologic Live · refreshed every 30 min

Target snapshot

M923 (M923) — Momenta Pharmaceuticals, Inc.. M923 is a monoclonal antibody that targets and modulates IgG glycosylation to enhance immune function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
M923 TARGET M923 Momenta Pharmaceuticals, Inc. phase 3 Monoclonal antibody (glycoengineered) IgG Fc glycosylation / Fc receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (glycoengineered) class)

  1. Momenta Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). M923 — Competitive Intelligence Brief. https://druglandscape.com/ci/m923. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: